Acasti Pharma Inc Class A ACST
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ACST is a good fit for your portfolio.
News
-
Acasti Announces Second Quarter 2024 Financial Results and Business Highlights
-
Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial
-
Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)
-
Acasti Announces $7.5 Million Private Placement Equity Financing
-
Acasti Pharma, FDA Agree on GTX-104 Phase 3 Trial Protocol
Trading Information
- Previous Close Price
- $2.23
- Day Range
- $2.19–2.24
- 52-Week Range
- $1.72–5.05
- Bid/Ask
- $2.19 / $2.24
- Market Cap
- $20.58 Mil
- Volume/Avg
- 701 / 50,033
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Acasti Pharma Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery all of which could help to increase treatment compliance and improve patient outcomes.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 32
- Website
- https://www.acastipharma.com
Valuation
|
Metric
|
ACST
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.31 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
ACST
Financial Strength
|
Metric
|
ACST
|
|---|---|
Quick Ratio | 19.93 |
Current Ratio | 20.68 |
Interest Coverage | — |
Quick Ratio
ACST
Profitability
|
Metric
|
ACST
|
|---|---|
Return on Assets (Normalized) | −9.03% |
Return on Equity (Normalized) | −10.69% |
Return on Invested Capital (Normalized) | −11.25% |
Return on Assets
ACST
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Dnng | $445.3 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Hqxxp | $91.1 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Rcykn | $91.1 Bil | |
SGEN
| Seagen Inc Ordinary Shares | Pxlymm | $40.7 Bil | |
MRNA
| Moderna Inc | Rjyh | $30.7 Bil | |
ARGX
| argenx SE ADR | Thmv | $27.7 Bil | |
BNTX
| BioNTech SE ADR | Dbsw | $24.1 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Qwxvyn | $22.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Gswdm | $17.7 Bil | |
INCY
| Incyte Corp | Zrnby | $12.4 Bil |